Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum

Biotechnol Lett. 2006 Jun;28(11):837-41. doi: 10.1007/s10529-006-9007-9. Epub 2006 May 31.

Abstract

Ganoderic acid, from Ganoderma lucidum, at 8 microg/ml inhibited replication of hepatitis B virus (HBV) in HepG2215 cells over 8 days. Production of HBV surface antigen and HBV e antigen were 20 and 44% of controls without ganoderic acid. Male KM mice were significantly protected from liver injury, induced with carbon tetrachloride, by treatment with ganoderic acid at 10 mg and 30 mg/kg x d (by intravenous injection) 7 days. Ganoderic acid at the same dosage also significantly protected the mice from liver injury induced by M. bovis BCG plus lipopolysaccharide (from Escherichia coli 0127:B8).

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Cells, Cultured / virology
  • Drugs, Chinese Herbal / pharmacology*
  • Escherichia coli / chemistry
  • Hepatitis B / drug therapy*
  • Hepatitis B virus / drug effects*
  • Hepatitis, Animal / chemically induced
  • Hepatitis, Animal / microbiology
  • Hepatitis, Animal / prevention & control*
  • Heptanoic Acids / isolation & purification
  • Heptanoic Acids / pharmacology*
  • Humans
  • Lipopolysaccharides
  • Male
  • Mice
  • Models, Animal
  • Mycobacterium bovis
  • Reishi / chemistry
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Drugs, Chinese Herbal
  • Heptanoic Acids
  • Lipopolysaccharides